Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, NigeriaInstitute for Advanced Medical Research and Training, University of Ibadan, Ibadan, Nigeria.
Clin Drug Investig. 2004;24(3):149-55. doi: 10.2165/00044011-200424030-00003.
To evaluate the efficacy of cotrimoxazole in the treatment of Plasmodium falciparum malaria and to compare the efficacy of cotrimoxazole with that of pyrimethamine-sulfadoxine, a second-line antimalarial drug, in an area of high malaria transmission.
Children aged between 10 months and 10 years with clinical and parasitological evidence of P. falciparum malaria were randomised to receive either cotrimoxazole or pyrimethamine-sulfadoxine. 145 children (73 and 72, respectively, in the cotrimoxazole and pyrimethamine-sulfadoxine groups) completed the study per protocol and were evaluated.
Pretreatment clinical and parasitological parameters were similar in the two treatment groups. The time to clear fever and other symptoms was similar in the two groups: 1.94 +/- 1.10 days versus 2.20 +/- 0.96 days, p > 0.05. Parasite clearance times were also similar: 2.62 +/- 0.91 days versus 2.94 +/- 1.17 days, respectively, for cotrimoxazole and pyrimethamine-sulfadoxine; p > 0.05. The cure rates on days 14, 21 and 28 were, respectively, 84.9, 75.3 and 74.0% for the cotrimoxazole group and 84.7, 80.5 and 75.0% for the pyrimethamine-sulfadoxine group. Both drugs were well tolerated.
These results indicate that cotrimoxazole has similar efficacy to pyrimethamine-sulfadoxine in the treatment of acute uncomplicated P. falciparum malaria in children resident in an endemic area of Southwest Nigeria.
评估复方新诺明治疗恶性疟原虫疟疾的疗效,并比较复方新诺明与抗疟二线药物氨苯砜-磺胺甲噁唑在疟疾高度传播地区的疗效。
年龄在 10 个月至 10 岁之间,有临床和寄生虫学证据表明患有恶性疟原虫疟疾的儿童,随机分为复方新诺明或氨苯砜-磺胺甲噁唑组。145 名儿童(复方新诺明组和氨苯砜-磺胺甲噁唑组分别为 73 名和 72 名)完成了该研究。
两组患儿治疗前的临床和寄生虫学参数相似。两组退热及其他症状缓解时间相似:1.94±1.10 天对 2.20±0.96 天,p>0.05。寄生虫清除时间也相似:复方新诺明组和氨苯砜-磺胺甲噁唑组分别为 2.62±0.91 天和 2.94±1.17 天,p>0.05。第 14、21 和 28 天的治愈率分别为复方新诺明组 84.9%、75.3%和 74.0%,氨苯砜-磺胺甲噁唑组分别为 84.7%、80.5%和 75.0%。两种药物均耐受良好。
这些结果表明,复方新诺明治疗尼日利亚西南部流行地区儿童急性无并发症恶性疟原虫疟疾的疗效与氨苯砜-磺胺甲噁唑相似。